TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:09
Bolt Biotherapeutics Inc. ( BOLT ) https://www.boltbio.com
0.51USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-52.31%
BOLT
SPY
32.66%
-88.61%
BOLT
SPY
108.59%
BOLT
0.00%
SPY
302.52%
BOLT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
19.55
-16.07
0.22
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.30
2.00
0.27
-247.12
0.00
0.23
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1441.10
100.00
-800.14
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-137.10
-42.19
0.00
Other Earnings and Cash Flow Stats:
Bolt Biotherapeutics Inc. ( BOLT ) Net Income TTM ($MM) is -65.09
Bolt Biotherapeutics Inc. ( BOLT ) Operating Income TTM ($MM) is -75.90
Bolt Biotherapeutics Inc. ( BOLT ) Owners' Earnings Annual ($MM) is 0.00
Bolt Biotherapeutics Inc. ( BOLT ) Current Price to Owners' Earnings ratio is 0.00
Bolt Biotherapeutics Inc. ( BOLT ) EBITDA TTM ($MM) is -74.02
Bolt Biotherapeutics Inc. ( BOLT ) EBITDA Margin is -800.14%
Capital Allocation:
Bolt Biotherapeutics Inc. ( BOLT ) has paid 0.00 dividends per share and bought back -0.382502 million shares in the past 12 months
Bolt Biotherapeutics Inc. ( BOLT ) has reduced its debt by 2.68 million USD in the last 12 months
Capital Structure:
Bolt Biotherapeutics Inc. ( BOLT ) Interest-bearing Debt ($MM) as of last quarter is 18
Bolt Biotherapeutics Inc. ( BOLT ) Annual Working Capital Investments ($MM) are -4
Bolt Biotherapeutics Inc. ( BOLT ) Book Value ($MM) as of last quarter is 72
Bolt Biotherapeutics Inc. ( BOLT ) Debt/Capital as of last quarter is 25%
Other Balance Sheet Stats:
Bolt Biotherapeutics Inc. ( BOLT ) has 9 million in cash on hand as of last quarter
Bolt Biotherapeutics Inc. ( BOLT ) has 18 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Bolt Biotherapeutics Inc. ( BOLT ) has 38 common shares outstanding as of last quarter
Bolt Biotherapeutics Inc. ( BOLT ) has 0 million USD of preferred stock value
Academic Scores:
Bolt Biotherapeutics Inc. ( BOLT ) Altman Z-Score is -6.64 as of last quarter
Bolt Biotherapeutics Inc. ( BOLT ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Bolt Biotherapeutics Inc. ( BOLT ) largest shareholder is owning shares at 0.00 ($MM) value
William P Quinn(an insider) Bought 7500 shares of Bolt Biotherapeutics Inc. ( BOLT ) for the amount of $7125.00 on 2023-12-12
3.46% of Bolt Biotherapeutics Inc. ( BOLT ) is held by insiders, and 58.19% is held by institutions
Bolt Biotherapeutics Inc. ( BOLT ) went public on 2021-02-05
Other Bolt Biotherapeutics Inc. ( BOLT ) financial metrics:
FCF:-61.18
Unlevered Free Cash Flow:0.00
EPS:-1.59
Operating Margin:-1441.10
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-84.27
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Bolt Biotherapeutics Inc. ( BOLT ) :
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.